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Would Outcomes From the SYNTAX (Synergy
Between Percutaneous Coronary Intervention With
Taxus and Cardiac Surgery) Trial Have Differed With
Newer-Generation Drug-Eluting Stents?*
Vasim Farooq, MB, CHB,
Patrick W. Serruys, MD, PHD
Rotterdam, the Netherlands
Newer-generation drug-eluting stents (DES) have un-
equivocally led to signiﬁcant improvements in safety
compared with ﬁrst-generation DES (1–8). Given the
substantial clinical beneﬁts attained with newer-generation
DES, the obvious question remainsdwould outcomes from
the landmark SYNTAX (Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Surgery)
trial (9–12) have differed with newer-generation DES?
See page 1012
In this issue of JACC: Cardiovascular Interventions, Ribi-
chini et al. (13) present important ﬁndings from the
randomized, multicenter EXECUTIVE (Evaluating Xience-
V in Multi-Vessel Disease) pilot trial, comparing the newer-
generation everolimus-eluting stent (EES) (Xience V, Abbott
Vascular, Santa Clara, California) against the ﬁrst-generation
paclitaxel-eluting stent (PES) (Taxus Express, Boston
Scientiﬁc, Natick, Massachusetts) in the treatment of multi-
vessel coronary artery disease. The primary outcome was
angiographic, namely, late lumen loss, and demonstrated the
superiority of EES (all lesions late lumen loss: EES 0.05 
0.51 mm vs. PES 0.24 0.50 mm, p< 0.001). Although the
study was clearly underpowered for clinical outcomes, obser-
vations of numerical differences in 1-year major ad-
verse cardiac events of 11.1% in the randomizedEES arm, and
16.5% in the randomized PES arm are difﬁcult to ignore, and
offer a unique insight into the potential beneﬁt of newer-
generation DES in the treatment of multivessel disease.*Editorials published in JACC: Cardiovascular Interventions reﬂect the views of the
authors and do not necessarily represent the views of JACC: Cardiovascular Interven-
tions or the American College of Cardiology.
From the Department of Interventional Cardiology, Erasmus University Medical
Centre, Thoraxcenter, Rotterdam, the Netherlands. Both authors have reported that
they have no relationships relevant to the contents of this paper to disclose.There are, however, a number of caveats to the EXECU-
TIVE trial that should be highlighted. Firstly, in keepingwith
the U.S. and European revascularization guidelines (14–16),
the EXECUTIVE trial focused primarily on low SYNTAX
score (<23) (11,17,18) subjects, having been recruited in
approximately 95% of the EES and PES treatment arms
(mean SYNTAX score: 12.7  5.2). How generalizable the
results of the EXECUTIVE trial are to subjects with more
complex multivessel disease, therefore, remains unclear.
Secondly, the EXECUTIVE trial lacked an all-comers
design, with clinical and angiographic inclusion and exclusion
criteria, which somewhat limits translation of the study’s
ﬁndings to contemporary clinical practice, even in low
SYNTAX score subjects. For example, a history of congestive
cardiac failure or a left ventricular ejection <30%dfactors
previously shown to alter the threshold value of the SYNTAX
score in favor of coronary artery bypass grafting (CABG)
(19)dwere exclusion criteria. In the pre-SYNTAX era, such
restrictive trial designs comparing CABG with percutaneous
coronary intervention (PCI) were heavily criticized for
“cherry-picking” patients for randomization, despite the
randomized nature of these studies (20,21). Thirdly, the
EXECUTIVE trial was clearly underpowered to assess clin-
ical outcomes, and showed numerical differences in clinical
outcomes that could not be statistically corroborated.
Fourthly, the fact that complete revascularization almost
uniquely appeared to have been achieved in all randomized
patients, with consequent favorable outcomes (22,23), and
that an arbitrarily deﬁned limit of 4 planned stents per patient
was placed in the angiographic inclusion criteria, does imply
a further amount of selection bias in recruiting subjects.
The improved clinical outcomes with the EES in multi-
vessel disease (despite the described shortcomings of the
EXECUTIVE trial), coupled with similarly reported data
from the FLM Taxus (French Left Main Taxus) and the
LEMAX (LEft MAin Xience) registries, investigating left
main stenting with EES (24,25), and the known reductions
in stent thrombosis (ST) of newer-generation DES (1–8),
does imply that if newer-generation DES had been used in
the SYNTAX trial, there would have been a signiﬁcant
reduction in clinical events, particularly repeat revasculari-
zation and myocardial infarction.
As to whether reductions in mortality would be seen with
newer-generation DES in patients undergoing contempo-
rary PCI is entirely plausible (8). Large-scale reductions in
ST and their clinical sequelae with newer-generation DES
are ﬁrmly established in the literature, although the expected
reduction in mortality awaits conﬁrmation from randomized
trials (1–7). Conversely, in the SYNTAX trial, if the cardiac
mortality events related to ST were removed, based on
Academic Research Consortium (26) deﬁnitions of ST,
there would have been only a modest reduction in cardiac
mortality at 5 years. Namely, for deﬁnite ST, 5-year cardiac
mortality would be reduced from 9% to 8.5%, and for
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1024deﬁnite and probable ST, from 9% to 7.5% (27). The main
reason to account for this phenomenon may relate to the
hypothesis that bypass grafts protect coronary vessels from
future myocardial events for the lifespan of the graft,
particularly in more complex coronary artery disease where
the plaque burden and risk of a future cardiac event would
potentially be higher, compared with a subject with less
complex coronary artery disease. Conversely, stents would
only treat individual lesions (21,28).
The potential reduction in mortality with newer-genera-
tion DES in the SYNTAX trial would therefore be unlikely
to bridge the gap between CABG and PCI, particularly with
more complex coronary artery disease. This is exempliﬁed in
the SYNTAX score II (19,29), in which the SYNTAX score
was combined with clinical variables that were shown to alterFigure 1. Scatter Plots for Individual Patients in the Left Main and 3-Vessel Dise
The scatter plots for the left main and 3-vessel disease cohorts of the SYNTAX (Synerg
trial are based on the SYNTAX score II. The diagonal line represents identical mortality
of the diagonal line favor CABG (actual percentages shown in top left corner), an
Individual mortality predictions for CABG or PCI that could be statistically separated
parentheses in respective corners). Mortality predictions that could not be statistically
patients with similar 4-year mortality. 3VD ¼ 3-vessel disease; CABG ¼ coronary arte
vention. Legend and image are adapted and reproduced, with permission, from Farthe threshold value of the SYNTAX score so that equipoise
was achieved between CABG and PCI for long-term
mortality. Notably, subsets of patients were identiﬁed across
all tertiles of the SYNTAX score who would have
a mortality beneﬁt from undergoing CABG or PCI (Fig. 1).
It should, however, be emphasized that increasing anatom-
ical complexity, particularly in subjects with 3-vessel disease,
lead to a greater likelihood of a mortality beneﬁt to be
attained with CABG over PCI (Fig. 1).
In both the ongoing EXCEL (Evaluation of XIENCE
PRIME Everolimus Eluting Stent System [EECSS] or
XIENCE V EECSS Versus Coronary Artery Bypass
Surgery for Effectiveness of Left Main Revascularization)
trial (NCT01471522), investigating the treatment of
unprotected left main coronary artery disease, and thease Cohorts of the Randomized SYNTAX Trial (N ¼ 1,800)
y Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery)
predictions for CABG and PCI. Individual mortality predictions plotted to the left
d to the right favor PCI (actual percentages shown in bottom right corner).
with 95% conﬁdence (p < 0.05) are colored black (actual percentage shown in
separated with 95% conﬁdence (p > 0.05) are highlighted in gray, and identify
ry bypass grafting; LMS ¼ left main stem; PCI ¼ percutaneous coronary inter-
ooq et al. (19).
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1025planned SYNTAX Trial II, investigating the treatment of de
novo 3-vessel disease, the SYNTAX score and SYNTAX
score II, respectively, are being used to recruit subjects on the
grounds of patient safety (30). Further delineating the
boundaries between CABG and PCI is where further study
is heading to help best deﬁne the optimal revascularization
modality for individual patients with complex coronary
artery disease.
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